How would you approach a patient with metastatic colon cancer with biopsy-confirmed bone mets who has a significant decrease in CEA on FOLFOX but develops new bone lesions?  

Would you continue FOLFOX or switch to another agent?

KRAS WT, MSS, no targetable mutations

Answer from: Medical Oncologist at Academic Institution
Medical Oncologist at Dartmouth Cancer Center, Dartmouth-Hitchcock Medical Center
This phenomenon feels relatively common. I agree w...
Sign in or Register to read more

Answer from: Medical Oncologist at Community Practice